Gain Therapeutics, a clinical-stage biotech focused on small molecule therapeutics targeting protein misfolding diseases, advances its lead Parkinson’s candidate GT-02287 with positive Phase 1 safety data. The company leverages its proprietary Magellan™ drug discovery platform to identify novel allosteric sites critical for pipeline development. Despite scientific progress, Gain faces sustained negative operating profitability and cash flows, with a cash burn necessitating additional capital to fund operations beyond early 2026. Litigation risks related to warrant repricing claims add uncertainty to its financing outlook. Monitoring clinical milestones and partnership developments is essential to assess progress amid these financial constraints.